| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.8 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.011 | 0.8 |